SCHEMBL507552

SCHEMBL507552

N#Cc1ccc(CBr)nc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MBOAT4 Q96T53 1/20 0.39
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 2/20 0.37
GSK3B P49841 1/20 0.37
HPGD P15428 2/20 0.36
CYP19A1 P11511 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
CCR1 P32246 1/20 0.35
CYP2A6 P11509 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
XDH P47989 1/20 0.34
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30966731 1.00 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL27576276 0.84 KDM4E (0.40) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL2633134 0.79 CYP2A6 (0.48) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL17845779 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL453494 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL23171396 0.79 MEN1 (0.43) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL6245066 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL450943 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL17266360 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA
SCHEMBL453493 0.79 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MBOAT4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080069-A Phospholipid compounds and uses thereof 2026-05-26 CN disclosed
EP-4743175-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Aconcagua Bio, Inc. (US) 2026-05-20 EP disclosed
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
US-12583861-B2 Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application SANOFI (FR) 2026-03-24 US disclosed
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO INC (US) 2026-03-12 US disclosed
EP-4271674-B9 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-03-11 EP disclosed
US-12570666-B2 Furoindazole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2026-03-10 US disclosed
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2026-02-26 US disclosed
EP-4288438-B1 DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2026-02-18 EP disclosed
US-20260042760-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY ACONCAGUA BIO INC (US) 2026-02-12 US disclosed
EP-1202975-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2002-05-08 EP disclosed
US-20020037857-A1 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. 2002-03-28 US disclosed
EP-1182207-A2 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. (US) 2002-02-27 EP disclosed
WO-2002014349-A2 NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION CORVAS INTERNATIONAL, INC. (US) 2002-02-21 WO disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001087854-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO disclosed
WO-2000069834-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2000-11-23 WO disclosed
US-6071917-A ANALGESICS; ANTIINFLAMMATORY AGENTS; ESPECIALLY FOR THE TREATMENT OF ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS; COMPETITIVE BINDING AT RECEPTORS FOURNIER INDUSTRIE ET SANTE (FR) 2000-06-06 US disclosed
EP-0925295-A1 N-BENZENESULPHONYL-L-PROLINE DERIVATIVES AS BRADYKININ B2 AGONISTS FOURNIER INDUSTRIE ET SANTE (FR) 1999-06-30 EP disclosed
WO-1998003503-A1 N-BENZENESULPHONYL-L-PROLINE DERIVATIVES AS BRADYKININ B2 AGONISTS FOURNIER INDUSTRIE ET SANTE (FR) 1998-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042760-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY NPY1R, CALCRL, SCTR KDM4E 4872/4885ALDH1A1 3320/4885L3MBTL1 3326/4885
US-12583861-B2 Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application TLR7, TLR8, TLR6 KDM4E 2479/4885ALDH1A1 3447/4885L3MBTL1 4094/4885
US-20020037857-A1 Non-covalent inhibitors of urokinase and blood vessel formation PLAU, PLAT, PLG KDM4E 2490/4885ALDH1A1 2751/4885L3MBTL1 1309/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 KDM4E 1491/4885ALDH1A1 2216/4885L3MBTL1 2432/4885
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, CTTN KDM4E 3413/4885ALDH1A1 2666/4885L3MBTL1 3673/4885
US-12570666-B2 Furoindazole derivatives FURIN, CYP2F1, CYP3A7 KDM4E 3858/4885ALDH1A1 510/4885L3MBTL1 3183/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 KDM4E 3715/4885ALDH1A1 385/4885L3MBTL1 2965/4885
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SCTR, SSTR1, NPY1R KDM4E 4878/4885ALDH1A1 2807/4885L3MBTL1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.